4.8 Article

Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial

期刊

NATURE MEDICINE
卷 28, 期 9, 页码 1813-+

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41591-022-01956-3

关键词

-

资金

  1. California Institute for Regenerative Medicine [DR2-05320, CLIN2-09284]

向作者/读者索取更多资源

This study demonstrates that human neural progenitor cells modified to release GDNF can be safely transplanted into the spinal cord of ALS patients, providing support cells and GDNF delivery for over 3 years. The transplantation of CNS10-NPC-GDNF has shown to protect spinal motor neurons and have no negative impact on motor function in the treated leg. Furthermore, the transplanted cells have been found to survive and produce GDNF in tissue analysis.
Amyotrophic lateral sclerosis (ALS) involves progressive motor neuron loss, leading to paralysis and death typically within 3-5 years of diagnosis. Dysfunctional astrocytes may contribute to disease and glial cell line-derived neurotrophic factor (GDNF) can be protective. Here we show that human neural progenitor cells transduced with GDNF (CNS10-NPC-GDNF) differentiated to astrocytes protected spinal motor neurons and were safe in animal models. CNS10-NPC-GDNF were transplanted unilaterally into the lumbar spinal cord of 18 ALS participants in a phase 1/2a study (NCT02943850). The primary endpoint of safety at 1 year was met, with no negative effect of the transplant on motor function in the treated leg compared with the untreated leg. Tissue analysis of 13 participants who died of disease progression showed graft survival and GDNF production. Benign neuromas near delivery sites were common incidental findings at post-mortem. This study shows that one administration of engineered neural progenitors can provide new support cells and GDNF delivery to the ALS patient spinal cord for up to 42 months post-transplantation. A phase 1/2a study shows that human neural progenitor cells modified to release the growth factor GDNF are safely transplanted into the spinal cord of patients with ALS, with cell survival and GDNF production for over 3 years.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据